ACADIA Pharmaceuticals Appoints New CEO, Shares Dip

Acadia Pharmaceuticals Inc. (ACAD) saw its stock price drop by 4.11% following the announcement of Catherine Owen Adams as its new CEO. Adams, who brings extensive experience from Bristol Myers Squibb and Johnson & Johnson, is expected to lead Acadia through its next growth phase. This news comes as the company continues to navigate the market with its approved products, NUPLAZID and DAYBUE.

V2X VVX: An Attractive Buy with Upgraded Zacks Rank #2

V2X VVX has been upgraded to a Zacks Rank #2 (Buy), indicating a positive earnings outlook and potential for price appreciation. The Zacks Rank system, based on earnings estimate revisions, has a strong track record of identifying stocks with market-beating returns. V2X’s improved earnings estimates and placement in the top 20% of Zacks-covered stocks suggest a promising future for the company.

Compass Minerals Shares Soar on Strong Q3 Revenue

Compass Minerals Intl Inc (CMP) shares surged on Tuesday after the company announced preliminary third-quarter revenue exceeding estimates. The Salt and Plant Nutrition segments showed strong performance, driving the positive results. The company is also actively addressing past accounting issues and has revised its full-year revenue outlook.

Embraer Shares Dip as Boeing Arbitration Concludes, Paying $150 Million

Embraer’s stock price fell on Monday after the company announced the conclusion of its arbitration with Boeing. Boeing will pay Embraer $150 million to settle the dispute stemming from the termination of a $4.2 billion deal in 2020. Despite the settlement, Embraer continues to see positive developments with a recent contract to sell A-29 Super Tucano aircraft to Uruguay and an anticipated increase in deliveries in the latter half of 2024.

Exit mobile version